Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Single Dose Escalation of P1101 in Healthy Males
NCT05129644Phase 1Completed
- Sponsor
- PharmaEssentia
- Start
- Nov 2009
- Primary completion
- Jun 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ropeginterferon alfa-2b in hepatitis C (HCV), hepatitis B (HBV) and polycythemia vera (PV) (7 arms), sponsored by PharmaEssentia. Primary endpoints: Adverse Event at Day 35, Area Under the Curve at 672 hours and 3 more. Started Nov 2009; status: completed.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
hepatitis C (HCV)hepatitis B (HBV)polycythemia vera (PV)
Beyond the preview
Go deeper on NCT05129644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05129644.